Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Investigator
- Ali Ataya
- Ages
- 18 Years - N/A
- Sexes
- All
Clinical trials
-
ROR-PH-303 (APD811-303) -
Prosera The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
- Investigator
- Ali Ataya
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Hemotag - Investigator
- Ali Ataya
-
United therapeutics 301 Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)鈥�
- Investigator
- Ali Ataya
- Ages
- 18 Years - N/A
- Sexes
- All